Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEN1055
- Development stage
- Discontinued
- Lead developer
- Genmab
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GEN1055 is an investigational bispecific monoclonal antibody developed using Genmab's HexaBody technology. It targets OX40 (also known as CD134), a costimulatory receptor expressed on activated T cells. Unlike traditional OX40 agonists that require Fcγ receptor crosslinking for activity, GEN1055 is designed to be Fcγ receptor crosslinking-independent and uses the HexaBody format to enhance complement-dependent cytotoxicity (CDC) by promoting antibody hexamerization on the cell surface. This leads to superior C1q binding and enhanced immune activation against tumor cells[1][2][7]. The drug is being evaluated in clinical trials as monotherapy and in combination with pembrolizumab (an anti-PD-1 antibody) with or without chemotherapy for the treatment of malignant solid tumors[3][4][5]. The primary goals are to assess safety, determine optimal dosing regimens, and evaluate preliminary antitumor efficacy.
- Other names
- GEN1055GEN-1055GEN 1055HexaBody-OX40HexaBody-OX-40HexaBody-OX 40BNT315BNT-315BNT 315
02
Targets
CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on GEN1055.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEN1055.